Analysis of Oral Hypoglycemic Drugs Consumption in Ukraine in 2015

Abstract

Diabetes is a global medical and social problem in the world, influence the quality and duration of patients life. According to official statistics in Ukraine in 2015 the number of patients with diabetes covered 2.81% of the total number of residents. For every registered patient there are 2.5 patients with unidentified diabetes. Based on these data, we can assume that in Ukraine there are about 3.6 million patients with diabetes (8.45% of population), of which 90% (3.24 million) are patients with type 2 diabetes (7.6% of population). The main method of treatment of patients with type 2 diabetes is the use of oral hypoglycemic drugs (OHDs). Most OHDs have high clinical efficacy, their use increases the duration and quality of patients life. The objective - determining the consumption of the OHDs in Ukraine in 2015. Calculation of OHDs consumption was carried out on the basis of the ATC/DDD-methodology. In Ukraine in 2015 total consumption of OHDs was 11.14 DIDs. This means that 1.1% of the population of Ukraine from the total number of residents received 1 DDD of oral hypoglycemic drugs daily. Taking into account the official statistics, the consumption of OHDs for patients with diabetes should cover 2.81% of the population, but real consumption of OHDs 2.6 times less than is necessary for all officially registered patients. When recalculating the consumption of OHDs, taking into account unregistered patients with type 2 diabetes in Ukraine (7.6% of the population), their consumption was 6.9 times less than the required amount. Thus, the calculated indicator of the consumption of OHDs in Ukraine is 2.6 to 6.9 times lower than necessary for the treatment of patients with diabetes. The incidence of diabetes in Ukraine in 2015 was significantly higher than the consumption of OHDs, which indicates an insufficient level of OHDs consumption.